Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

RegMed Daily Dialogue, 7/20/11, a market of moving parts

The 6 W’s: Who, what, where, when, why and what of it…

 

US stocks are “wobbling” mid-day with investors stepping back as unresolved debt issues in Washington and abroad fester.  With respect to the US debt ceiling, the US Treasury market has for months sent the message that it’s going up, whether on Aug. 2 or days after. The only question is what strings are attached to it …  

 

Regenerative medicine/stem cell universe is “suffering the summer doldrums yet, many are trading at a dramatic discount based on stages of development and trial status” on 7/20/11 The NASDAQ is DOWN -11.41 (-0.40%) to 2,815.11. The Dow is also DOWN -9.80 (-0.08%) to 12,577.62.  

 

Who’s UP today: Aastrom (ASTM), Advanced Cell Technology (ACTC.OB), Athersys (NASDAQ:ATHX), Fibrocell (NASDAQ:FCSC), International Stem Cell (OTCQB:ISCO), Neuralstem (AMEX: CUR), Pluristem (NASDAQ:PSTI), Opexa (OPXA), ReNeuron (LSE: RENE.L), and Tengion (TNGN) are up …

 

What’s driving the regenerative medicine/stem cell market … NOT MUCH but … but, another financing is getting … fulfilled … sentiment is still focused on the future …

 

NeoStem (AMEX: NBS is about to close their offering by 7/22: Positions the shares for a serious upside … based on an extended runway, a recent acquisition of an advanced (P2 – Amorcyte) heart therapy, name institutional investors, an improved business climate for PCT (2 existing clinical stage biopharmaceutical corporate clients have chosen to expand their development activities) and an expectation of a possible divestiture no later than 2012 from their Chinese holdings … More to follow … at this price, I recommend being a BUYER … upon the closing!

International Stem Cell, Preclinical Animal Studies of Neuronal Cells Derived From Human Parthenogenetic Stem Cells: ISCO.OB initiated a series of preclinical animal studies of neuronal cells derived from ISCO’s proprietary pluripotent stem cells. The studies will evaluate the in vivo safety and tumorigenicity of neuronal cells derived from ISCO’s proprietary human parthenogenetic stem cells (hpSC), as well as their ability to develop into functioning dopaminergic neuron–like cells, a key milestone towards creating a cell-based therapy for Parkinson’s disease (PD). Still is pre-clinical … and moving beyond the crèmes!

 ReNeuron Group (LSE: RENE.L) has appointed 2 further non-executive directors and elevated 1 to chairman: Bryan Morton, a non-executive director since 2008, is to become chairman, beginning August. He is replacing Professor Trevor Jones, who will establish and chair a scientific and strategic advisory committee. The 2 new non-executive directors are: John Berriman and Simon Cartmell. Berriman is currently chairman of Heptares Therapeutics and deputy chairman of Algeta (an Oslo Stock Exchange-listed firm). Cartmell was, until June 2010, CEO at ApaTech, which he built into a leader orthbiologics firm that was sold to Baxter International for US$330M in March last year. New BOD blood always have better line extensions, eyes and views …

 Biotechnology Bounces Back With 46% Rise in Venture Capital:   Venture-capital funding in biotechnology companies jumped 46% in Q/2, as investors looked to replenish their portfolios after an increase in acquisitions and initial public offerings. Biotechnology companies attracted $1.24B in 116 deals. Biotech had garnered about $847M in 97 Q/1 investments… so the sentiment is still … good and not dead!  

Arteriocyte receives $1M Award to advance its NANEX™ Technology:   Arteriocyte, who develops proprietary stem cell and tissue engineering based therapies was award a grant from the Ohio Department of Development’s Third Frontier Commission for its “Development and Commercialization of Hematopoietic Stem Cell Expansion for Clinical Applications” to accelerate Good Manufacturing Practices (GMP) manufacturing of its NANEX™ technology for clinical use under the product name HemaEx. NANEX™ technology is a biofunctional nanofiber-based 3D scaffold designed to mimic the bone marrow environment, permitting rapid ex vivo proliferation of hematopoietic stem cells with minimal differentiation. This technology was licensed from John Hopkins University to enhance proprietary stem cell therapies targeting cardiovascular disease and cancer. Arteriocyte launched the technology commercially as a research-use “NANEX™ Hematopoietic stem cell expansion kit” in 12/10. This kit, combining NANEX™ culture ware with proprietary culture medium and growth factors, enables scientists to rapidly expand HSCs for their preclinical research.